Will Epkinly become a game-changer in the blood cancer mkt?
By Hwang, Byung-woo | translator Kang, Shin-Kook
24.07.12 05:49:34
가나다라
0
Highlights the role of bispecific antibodies in the third-line treatment of DLBCL, an area that lacks options
Epkinly’s approval study showed a median survival of 19.4 months, confirming the potential on extended patient survival
May settle as a complementary option to CAR-T therapies...reimbursement issue a concern
The arrival of bispecific antibody-based therapies in Korea is expected to shift the blood cancer treatment market paradigm.
The industry is welcoming the introduction of a new treatment option, as an unmet need exists in diffuse large B-cell lymphoma (DLBCL), which has a poor prognosis even after three or later lines of treatments.
▲AbbVie hosted a press conference on the 10th to highlight the significance of Epkinly’s approval. Professor Jin Seok Kim. Department of Hematology-Oncology at Severance Hospital, is presenting data related to blood cancer.
AbbVie hosted a press conference on the 10th to celebrate the launch of 'Epkinly (epcoritamab)’ as a third-line treatment for DLBCL and highlight the implications of the approval. Epkinly was approved by the Ministry of Food and Drug Safety in late June for the treatment of adult patients with relapsed or refractory DLBCL who have received 2
Hwang, Byung-woo(tuai@dailypharm.com)
If you want to see the full article, please JOIN US (click)